Stock Analysis on Net

Merck & Co. Inc. (NYSE:MRK)

Balance Sheet: Assets
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Merck & Co. Inc., consolidated balance sheet: assets (quarterly data)

US$ in millions

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Cash and cash equivalents 6,841 8,605 5,660 9,707 12,694 11,145 9,675 8,556 8,096 10,016 8,575 6,981 8,062 7,356 11,103 7,425 9,676 7,869 6,659 8,076
Short-term investments 252 168 718 680 498 103 453 372 7 774 149 446 722
Accounts receivable, net of allowance for doubtful accounts 10,349 10,394 11,030 10,415 9,450 9,482 9,643 9,828 9,230 8,571 7,843 8,235 7,851 8,422 7,577 8,182 6,778 8,442 7,964 7,608
Inventories, excludes inventories classified in Other assets 6,358 6,131 5,930 5,863 5,911 5,614 5,535 5,774 5,953 5,603 5,499 6,402 6,310 6,128 6,056 5,846 5,978 5,855 5,847 5,712
Other current assets 8,368 6,656 6,639 6,737 7,169 7,217 6,810 6,654 6,987 6,868 6,748 5,291 5,541 4,671 4,607 4,714 4,277 3,827 3,382 3,233
Current assets 32,168 31,954 29,977 33,402 35,722 33,561 32,116 31,184 30,266 31,058 28,665 26,909 27,764 26,577 29,343 26,174 27,483 26,142 24,298 25,351
Investments 252 1,306 1,214 1,290 1,015 984 238 316 370 435 411 544 785 1,372 1,251 555 1,469 2,111 3,779 5,621
Property, plant and equipment, at cost, net of accumulated depreciation 23,051 22,526 22,231 21,758 21,422 20,424 20,059 19,747 19,279 18,565 18,064 18,295 17,986 16,919 15,789 15,269 15,053 14,287 13,862 13,506
Goodwill 21,197 21,183 21,195 21,209 21,204 21,160 21,213 21,258 21,264 18,862 18,873 20,212 20,238 20,248 20,067 19,767 19,425 19,480 19,490 18,170
Other intangibles, net 18,011 19,199 19,665 19,857 20,269 21,368 22,497 23,022 22,933 13,384 13,622 14,401 14,604 16,677 16,566 16,096 14,196 12,307 13,381 10,999
Other assets 11,996 10,559 10,187 10,280 9,528 9,584 10,972 11,141 11,582 11,190 11,053 10,486 10,211 8,007 7,599 7,052 6,771 9,004 9,155 8,707
Noncurrent assets 74,507 74,773 74,492 74,394 73,438 73,520 74,979 75,484 75,428 62,436 62,023 63,938 63,824 63,223 61,272 58,739 56,914 57,189 59,667 57,003
Total assets 106,675 106,727 104,469 107,796 109,160 107,081 107,095 106,668 105,694 93,494 90,688 90,847 91,588 89,800 90,615 84,913 84,397 83,331 83,965 82,354

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).


Assets: Selected Items

Balance sheet item Description The company
Current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Merck & Co. Inc. current assets increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Property, plant and equipment, at cost, net of accumulated depreciation Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Merck & Co. Inc. property, plant and equipment, at cost, net of accumulated depreciation increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Noncurrent assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Merck & Co. Inc. noncurrent assets increased from Q2 2023 to Q3 2023 but then slightly decreased from Q3 2023 to Q4 2023 not reaching Q2 2023 level.
Total assets Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Merck & Co. Inc. total assets increased from Q2 2023 to Q3 2023 but then slightly decreased from Q3 2023 to Q4 2023.

Current Assets: Selected Items

Balance sheet item Description The company
Cash and cash equivalents Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Merck & Co. Inc. cash and cash equivalents increased from Q2 2023 to Q3 2023 but then slightly decreased from Q3 2023 to Q4 2023 not reaching Q2 2023 level.
Short-term investments Amount of investment in marketable security, classified as current. Merck & Co. Inc. short-term investments decreased from Q2 2023 to Q3 2023 but then slightly increased from Q3 2023 to Q4 2023.
Accounts receivable, net of allowance for doubtful accounts Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Merck & Co. Inc. accounts receivable, net of allowance for doubtful accounts decreased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Inventories, excludes inventories classified in Other assets Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. Merck & Co. Inc. inventories, excludes inventories classified in Other assets increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.